Foveal LLP Independent Investment Research Foveal Research

In newly published data from Merck /Moderna’s PD1 + mRNA cancer vaccine trial, efficacy may be flattered by Keytruda alone control arm under

As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients. The failure of Merck’s TIGIT+PD1 combo to beat second line

We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a

Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SK

Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...

Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...

Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s...

PD1 market continues to shrink, but Bristol’s failure not good news for rivals BMY announced Friday that its pivotal phase III study of...

Pressure on consensus: We have long argued all IO competitors will have to better Bristol’s Opdivo + Yervoy combination in the biggest...

New ASCO 2016 data continues to support lower than consensus potential revenues, modest anti PD-L1 efficacy and more doubts over chemo...